spartalizumab + bevacizumab + mFOLFOX6

spartalizumab + bevacizumab + mFOLFOX6 is an experimental combination regimen for the treatment of advanced or metastatic solid tumors, most notably being tested in metastatic colorectal cancer. - **Spartalizumab** is a monoclonal antibody immune checkpoint inhibitor targeting PD-1, developed for the modulation of the immune system to recognize and attack tumor cells. - **Bevacizumab** is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting tumor angiogenesis. - **mFOLFOX6** is a chemotherapy regimen consisting of oxaliplatin, leucovorin (folinic acid), and fluorouracil (5-FU), targeting rapidly dividing tumor cells by interfering with DNA synthesis and function. This combination is being tested as a first-line or subsequent-line regimen in patients with advanced malignancies such as metastatic colorectal cancer to exploit synergistic effects between immunotherapy, antiangiogenic therapy, and cytotoxic chemotherapy[2][1].

Other names

modified FOLFOX6folinic acid + fluorouracil + oxaliplatin